Hemab Therapeutics Holdings, Inc.
COAG
$54.94
$0.991.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 80.43% | 68.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 62.42% | 42.58% | |||
| Operating Income | -62.42% | -42.58% | |||
| Income Before Tax | -97.07% | -46.33% | |||
| Income Tax Expenses | 2,325.00% | 106.32% | |||
| Earnings from Continuing Operations | -97.80% | -48.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -97.80% | -48.22% | |||
| EBIT | -62.42% | -42.58% | |||
| EBITDA | -62.73% | -42.79% | |||
| EPS Basic | 93.79% | -48.22% | |||
| Normalized Basic EPS | 94.40% | -46.33% | |||
| EPS Diluted | 93.79% | -48.22% | |||
| Normalized Diluted EPS | 94.40% | -46.33% | |||
| Average Basic Shares Outstanding | 3,083.01% | 0.00% | |||
| Average Diluted Shares Outstanding | 3,083.01% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||